Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Anticoagulation and Activation - Comparison in Continuous Renal Replacement Therapy

This study has been withdrawn prior to enrollment.
(A main person involved left the site)
Information provided by (Responsible Party):
Klinik für Anästhesiologie, Heinrich-Heine University, Duesseldorf Identifier:
First received: January 12, 2011
Last updated: August 19, 2015
Last verified: August 2015
Actual clinical practice predominantly makes use of heparin (systemically) or citrate regionally as anticoagulation in the extracorporeal circulation for renal replacement therapy. We aim to find out if different anticoagulation strategies may lead to different levels of platelet activation and whole blood coagulation. Regarding coagulation activation, it remains uncertain if there is an advantage for one of these methods. However, it is of major interest to minimize the risk of any additional clotting activation via extracorporeal circulation in these usually critically ill patients.

Kidney Replacement Disorder

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Platelet Function, Whole Blood Coagulation and Fibrinolysis During Continuous Renal Replacement Therapy - a Comparison of Citrate and Heparin Anticoagulation

Resource links provided by NLM:

Further study details as provided by Heinrich-Heine University, Duesseldorf:

Primary Outcome Measures:
  • Filter life time of continuous renal replacement therapy [ Time Frame: Individual time point, standardized ] [ Designated as safety issue: Yes ]
    Filter life time measured in hours of duration of continuos renal replacement therapy, filter life time end, when system clotts.

Secondary Outcome Measures:
  • Activation of coagulation [ Time Frame: beginning of hemodialysis, 1,2,4,12,24,28,72 hours after start of hemodialysis ] [ Designated as safety issue: No ]
    blood samples for multiplate, rotem and systemic coagulation paramters

Enrollment: 0
Study Start Date: January 2011
Estimated Study Completion Date: February 2015
Estimated Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
10 Patients undergoing continuous renal replacement therapy using heparin for providing anticoagulation. Blood samples taken at 8 predefined timepoints.
10 Patients undergoing continuous renal replacement therapy using citrate for providing anticoagulation. Blood samples taken at 8 predefined timepoints.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Critical ill patients with acute renal failure and the need of continuous renal replacement therapy.

Inclusion Criteria:

  • Age > 18 years, acute renal failure with need for continuous veno-venous renal replacement therapy

Exclusion Criteria:

  • Age < 18 years, pregnancy, contraindications for one of the two anticoagulation methods, missing informed consent or disagreement in the progress of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01276392

Interdisciplinary Operative Intensive Care Unit, University Hospital Duesseldorf
Duesseldorf, NRW, Germany, 40225
Sponsors and Collaborators
Klinik für Anästhesiologie
Principal Investigator: Detlev Kindgen-Milles, Professor,MD Department of Anesthesiology, University Hospital Duesseldorf, Heinrich Heine University
  More Information

Responsible Party: Klinik für Anästhesiologie, Leiter Interdisziplinäre Operative Intensivstation ZOM-I, Heinrich-Heine University, Duesseldorf Identifier: NCT01276392     History of Changes
Other Study ID Numbers: 01-AHTSDKM 
Study First Received: January 12, 2011
Last Updated: August 19, 2015
Health Authority: Germany: Ethics Commission

Keywords provided by Heinrich-Heine University, Duesseldorf:
regional and systemical anticoagulation
continuous renal replacement therapy
rotational thrombelastometry

Additional relevant MeSH terms:
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action processed this record on October 25, 2016